Mark Benedyk is a well-rounded life sciences executive with a wealth of experience building businesses in the emerging and rapidly growing biotech and specialty pharma industries. He boasts a background that spans the full spectrum of company formation, fundraising, operations, staffing, and cash flow management. Mark has a unique talent for translating complex science and technology into a product concept that investors can understand and appreciate.

Mark Benedyk's career has taken him through early-stage drug discovery, as well as life cycle management for established products. He has worked in numerous start-ups, emerging companies, and established firms, including giants like Pfizer and Elan Pharmaceuticals (now Perrigo). Mark is an operating partner at Sweetwater Capital Advisors, LLC, where he brings his deep experience in operating executive leadership to bear.

Mark Benedyk is an active member of The National Association of Corporate Directors (NACD) and serves on multiple boards, including Accel-Rx, Pulmotect, Alafair Biosciences, and BioSigID. He has also acted as a director for The Center for Drug Development Ventures, Inc., Amarantus Biosciences, and The Pfizer Incubator, LLC. Mark is available for public and private company board roles, and he has served on three company compensation committees.

Mark Benedyk's educational background includes undergraduate degrees in microbiology and botany from the University of Michigan, as well as doctoral studies in genetics and developmental biology at Rockefeller University.